VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
GRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
GRDNGuardian Pharmacy Services, Inc.
$46.94$3.0B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksGRDNFinancials

Guardian Pharmacy Services, Inc. (GRDN) Income Statement

8Y historyFree accessUpdated daily

Revenue expanded from $300.0M in Q2 2024 to $371.1M in Q3 2026 while gross margin stayed in a narrow 19.4% to 23.0% band and operating margin fluctuated between 3.7% and 9.2%, indicating uneven operating leverage despite top-line growth.

Income StatementBalance SheetCash FlowRatios

GRDN Income Statement

Annual statement

GRDN Income Statement

Guardian Pharmacy Services, Inc. (GRDN) annual income statement — 8-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Sales/Revenue1.46B1.45B1.23B1.05B908.91M792.07M735.96M698.29M600.37M
Revenue Growth %4.85%17.93%17.42%15.1%14.75%7.62%5.39%16.31%-
Cost of Goods Sold1.13B1.17B984.04M837.88M723.04M630.81M588.96M554.83M477.33M
COGS % of Revenue-80.53%80.11%80.09%79.55%79.64%80.03%79.46%79.51%
Gross Profit327.08M282.04M244.37M208.31M185.87M161.26M147M143.46M123.03M
Gross Margin %22.45%19.47%19.89%19.91%20.45%20.36%19.97%20.54%20.49%
Gross Profit Growth %-15.42%17.31%12.08%15.25%9.7%2.47%16.6%-
Operating Expenses227.1M193.13M307.29M167.36M133.88M131.12M114.94M109.36M97.1M
OpEx % of Revenue-13.33%25.02%16%14.73%16.55%15.62%15.66%16.17%
Selling, General & Admin227.1M193.13M307.29M167.36M133.88M131.12M102.54M97.56M87.84M
SG&A % of Revenue-13.33%25.02%16%14.73%16.55%13.93%13.97%14.63%
Research & Development000000000
R&D % of Revenue---------
Other Operating Expenses00000012.4M11.8M9.26M
Operating Income99.98M88.91M-62.92M40.95M51.99M30.15M32.06M34.1M25.93M
Operating Margin %6.86%6.14%-5.12%3.91%5.72%3.81%4.36%4.88%4.32%
Operating Income Growth %-241.31%-253.67%-21.24%72.44%-5.97%-5.97%31.5%-
EBITDA123.44M111.25M-43.15M59.18M68.55M46.68M49.32M49.95M39.06M
EBITDA Margin %8.47%7.68%-3.51%5.66%7.54%5.89%6.7%7.15%6.51%
EBITDA Growth %52.55%357.83%-172.91%-13.67%46.86%-5.36%-1.26%27.86%-
D&A (Non-Cash Add-back)23.46M22.34M19.77M18.23M16.56M16.53M17.26M15.85M13.13M
EBIT105.81M74.09M-63.2M40.58M51.59M29.96M31.82M33.62M25.17M
Net Interest Income-648K-665K-3.28M-2.86M-1.93M-1.64M-2.16M-2.25M-1.9M
Interest Income000000000
Interest Expense648K665K3.28M2.86M1.93M1.64M2.16M2.25M1.9M
Other Income/Expense5.18M-15.49M-3.56M-3.23M-2.33M-1.82M-2.4M-2.73M-2.66M
Pretax Income105.16M73.42M-66.48M37.72M49.66M28.33M29.66M31.37M23.27M
Pretax Margin %7.22%5.07%-5.41%3.61%5.46%3.58%4.03%4.49%3.88%
Income Tax29.11M24.46M4.56M000000
Effective Tax Rate %27.68%33.32%-6.85%0%0%0%0%0%0%
Net Income74.77M49.22M-87.29M23.9M35.42M16.31M19.94M21.75M14.68M
Net Margin %5.13%3.4%-7.11%2.28%3.9%2.06%2.71%3.11%2.44%
Net Income Growth %85.81%156.39%-465.19%-32.52%117.12%-18.2%-8.29%48.15%-
Net Income (Continuing)76.05M48.96M-71.03M37.72M49.66M28.33M29.66M31.37M23.27M
Discontinued Operations000000000
Minority Interest12.48M12.16M7.3M31.65M33.2M29.39M28.59M27.72M25.86M
EPS (Diluted)1.170.78-1.770.390.580.270.330.360.24
EPS Growth %82.81%144.07%-553.85%-32.76%114.81%-18.18%-8.33%50%-
EPS (Basic)-0.79-1.770.390.580.270.330.360.24
Diluted Shares Outstanding63.92M63.3M62.01M60.84M60.84M60.84M60.84M60.84M60.84M
Basic Shares Outstanding63.34M62.39M62.01M60.84M60.84M60.84M60.84M60.84M60.84M
Dividend Payout Ratio---160.75%86.97%106.39%54.23%114.56%156.1%

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Thin margins under pricing pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Top-Line Growth Losing Momentum Recently

Based on the reported quarterly income statement data, GRDN's revenue grew from $300.0M in Q2 2024 to $371.1M in Q3 2026, but year-over-year growth decelerated to -1.7% in the latest quarter after running near 17-20% through much of 2025.

The sharp swing from double-digit expansion to a modest decline suggests the growth engine may be less durable than the earlier trajectory implied. Management's attribution of revenue pressure to IRA-mandated price reductions, if accurate, would indicate that reimbursement policy rather than volume loss is driving the slowdown, though this cannot be independently confirmed from the income statement alone. Investors should monitor whether volume growth can offset policy-driven price erosion over the next several quarters.

Gross Margin Anchored Near Twenty Percent

Reported gross margin has held in a narrow 19.4% to 23.0% band across the ten quarters shown, with the most recent 23.0% reading representing the high end of that range rather than a clear structural shift.

The stability of gross margin suggests GRDN's pricing spread on pharmaceutical dispensing is structurally thin, consistent with a distribution-heavy cost base. The recent uptick to 23.0% may reflect favorable generic mix or procurement timing, but a single quarter does not establish a durable expansion. Given the thin spread, any further reimbursement compression would likely reach operating profit quickly.

Operating Income Volatile Against Revenue Gains

Operating margin fluctuated between 3.7% and 9.2% over recent quarters, with SG&A holding roughly flat near $50M to $60M while revenue expanded, indicating the operating leverage is uneven rather than consistently positive.

Because SG&A appears largely fixed in the short run, quarterly operating income swings more with gross profit timing than with revenue scale alone. The peak 9.2% operating margin in Q4 2025 coincided with lower SG&A, which suggests cost timing rather than sustained efficiency may have driven that quarter. Operating leverage has not yet demonstrated a reliable upward trajectory.

Q3 2026 Earnings Miss Versus Revenue

Reported diluted EPS of $0.29 in Q3 2026 fell short of the cited $0.41 consensus despite revenue of $371.1M, while net margin compressed to 5.0% from 6.2% the prior quarter.

The gap between operating income of $25.1M and net income of $18.7M, combined with the EPS shortfall, suggests below-the-line items or tax effects absorbed a meaningful portion of operating profit. Stock-based compensation of $2.7M is modest relative to earnings and does not appear to be the primary driver. The divergence between revenue performance and earnings warrants investigation into the components of non-operating expense.

Earnings Base Vulnerable to Reimbursement Cuts

With a 6.8% operating margin and 5.0% net margin, GRDN's profit cushion is narrow, so modest reimbursement reductions or a further SG&A step-up could erase a large share of earnings based on reported figures.

The bull case relies on the company's low leverage and strong return on equity of 26.8%, but ROE is elevated relative to thin margins, which suggests returns are being amplified by a small equity base rather than by superior unit economics. Short-seller scrutiny would likely focus on the sequential revenue decline and the EPS miss as early signs of margin pressure. Investors should monitor whether the company can sustain profitability if IRA-related price declines persist.

GRDN — Frequently Asked Questions

Quick answers to the most common questions about buying GRDN stock.

What was Guardian Pharmacy Services, Inc.'s (GRDN) revenue in 2025?

For fiscal year 2025, Guardian Pharmacy Services, Inc. (GRDN) reported total revenue of $1.45B. This represents a 141.3% increase compared to $600.4M in 2018.

Is Guardian Pharmacy Services, Inc. (GRDN) profitable?

Guardian Pharmacy Services, Inc. (GRDN) is profitable, generating $49.2M in net income for the fiscal year ending 2025 with a net profit margin of 3.4%.

What is Guardian Pharmacy Services, Inc.'s operating profit margin?

Guardian Pharmacy Services, Inc. (GRDN) reported an operating income of $88.9M, resulting in an operating profit margin of 6.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Guardian Pharmacy Services, Inc.'s gross profit and gross margin?

Guardian Pharmacy Services, Inc. (GRDN) generated $282.0M in gross profit for the year, representing a gross profit margin of 19.5%. This demonstrates the company's core pricing power and production efficiency.